Pharma cos hit by new Patent Act concoction, filings drop 41% MUMBAI: Patent applications filed by Indian pharma firms have witnessed a sharp fall of 41% during FY08.Data provided by the Controller General of Patents shows that only 449 patent applications were filed in 2007-08 compared to 765 filed...
Costly Cancer Drug Offers Hope, but Also a Dilemma EXPERIMENTAL TREATMENT After participating in a clinical trial comparing Avastin with another new drug, Gailanne Reeh continued the regimen.Josh Haner/The New York Times It took only an instant for 58-year-old Gailanne Reeh to go from the...
Cancer drug Avastin has arguable benefits It took only an instant for 58-year-old Gailanne Reeh to go from the picture of health to death's door.By chance, her doctor noticed a lump under her arm during a routine exam.
It turned out to be advanced breast cancer.
The surgeon,...
For a big price, cancer drug buys small amount of time It took only an instant for 58-year-old Gailanne Reeh to go from the picture of health to death's door.By chance, her doctor noticed a lump under her arm during a routine exam.
It turned out to be advanced breast cancer.
Then the...
Novartis Gold Mine shot may stop killer meningitis Novartis AG biologist Rino Rappuoli says he may have found a way to wipe out meningitis B, a disease that can kill children within 24 hours of infection.Fifteen years after Rappuoli undertook his meningitis project, Basel, Switzerland...
Heart failure linked to sunitinib treatment NEW YORK (Reuters Health) - In a study published in the June 1st issue of Cancer, researchers report the development of symptomatic heart failure in nearly 3% of cancer patients soon after starting treatment with the multitargeted tyrosine...
TopAbstracts in Leukemias 07/02/2008 TopAbstracts in Leukemias are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 7 days.Over 2000 peer-reviewed...
SGX Pharmaceuticals Submits Investigational New Drug Application For SGX393 SGX Pharmaceuticals recently announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an internally developed, selective, orally-bioavailable...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO The standard of care for CML is Gleevec(R).Although Gleevec is a highly effective front-line therapy for CML, there are patients who relapse while on Gleevec or who are intolerant to the therapy.
In the majority of...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an internally developed, selective,...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SGX Pharmaceuticals (NASDAQ:SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an internally developed, selective, orally...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP - News) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP - News) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 San Diego The standard of care for CML is Gleevec(R).Although Gleevec is a highly effective front-line therapy for CML, there are patients who relapse while on Gleevec or who are intolerant to the therapy.
In the majority of...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an internally...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals SGXP today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an internally...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 , 2:00 AM EST The standard of care for CML is Gleevec(R).Although Gleevec is a highly effective front-line therapy for CML, there are patients who relapse while on Gleevec or who are intolerant to the therapy.
In the...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S.Food and Drug Administration for SGX393.
This compound is an...
